Investigational drug · Phase 2
BI 3034701
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Obesity, Overweight.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "BI 3034701"
First trial start
2026
Jun 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 3034701", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 3034701" as an intervention, largest first.
- A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07662122 · 345 participants · Start Jun 30, 2026 · Primary completion Jun 26, 2027
Drug: BI 3034701; Placebo matching BI 3034701 · For: Obesity; Overweight
Sites: Birmingham, Alabama; West Hills, California; Miami, Florida · 55 sites in all
- A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or ObesityPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06352437 · 125 participants · Start Jun 10, 2024 · Primary completion Oct 7, 2025
Drug: BI 3034701; Placebo matching BI 3034701 · For: Healthy
Sites: Berlin, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT07754474 · 70 participants (planned) · Start Sep 1, 2026 · Primary completion Jun 21, 2027
Drug: BI 3034701; Placebo · For: Overweight; Obesity
Sites: Mannheim, Germany
- A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or OverweightActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07693231 · 48 participants · Start Jul 21, 2026 · Primary completion Dec 22, 2026
Drug: BI 3034701; Placebo · For: Healthy; Obesity
Sites: Fukuoka, Fukuoka, Japan; Tokyo, Sumida-ku, Japan · 3 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07837648 · 30 participants (planned) · Start Oct 5, 2026 · Primary completion Dec 15, 2026
Drug: BI3034701 formulation II; BI3034701 formulation C1 · For: Healthy
Sites: Nottingham, United Kingdom
Boehringer IngelheimBoehringer Ingelheim
NCT07708493 · 8 participants · Start Aug 24, 2026 · Primary completion Oct 29, 2026
Drug: BI 3034701 (C-14) · For: Healthy
Sites: Budapest, Hungary
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.